D DOLBY LABORATORIES INC
| Market Cap | $6.15B |
| P/E Ratio | 26.08 |
| Forward P/E | 13.90 |
| Dividend Yield | 2.11% |
| Beta | 0.84 |
| 52W Range | $60.14 - $83.78 |
| # Hedge Funds | 0 |
| Sector | Industrials |
| Industry | Specialty Business Services |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 29 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Rollins Emily | Sale | 1,000 | $60.08 | $60.08K | 01 Apr 2026 | 01 Apr 2026 |
| Revankar ShriramSVP, Advanced Technology Group | Sale | 3,000 | $66.14 | $198.42K | 17 Feb 2026 | 17 Feb 2026 |
| Nicholson RyanVP, CAO and Corp. Controller | Sale | 2,667 | $66.38 | $177.02K | 13 Feb 2026 | 17 Feb 2026 |
| Couling John DSVP, Entertainment | Sale | 6,667 | $64.89 | $432.59K | 02 Feb 2026 | 04 Feb 2026 |
| John D CoulingSVP, Entertainment | Sale | 6,667 | $64.89 | $432.59K | 02 Feb 2026 | 04 Feb 2026 |
| YEAMAN KEVIN JPresident and CEO | Sale | 80 | $67.54 | $5.40K | 17 Dec 2025 | 17 Dec 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 6,671 | $67.24 | $448.53K | 17 Dec 2025 | 17 Dec 2025 |
| SHERMAN MARK ANDREWEVP, Gen. Counsel & Secretary | Sale | 2,491 | $67.26 | $167.55K | 17 Dec 2025 | 17 Dec 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 4,994 | $67.16 | $335.42K | 16 Dec 2025 | 17 Dec 2025 |
| SHERMAN MARK ANDREWEVP, Gen. Counsel & Secretary | Sale | 2,371 | $67.17 | $159.26K | 16 Dec 2025 | 17 Dec 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 21,772 | $66.64 | $1.45M | 16 Dec 2025 | 17 Dec 2025 |
| SHERMAN MARK ANDREWEVP, Gen. Counsel & Secretary | Sale | 6,738 | $66.58 | $448.59K | 16 Dec 2025 | 17 Dec 2025 |
| Couling John DSVP, Entertainment | Sale | 7,273 | $68.75 | $500.02K | 11 Dec 2025 | 15 Dec 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 28,168 | $66.99 | $1.89M | 09 Dec 2025 | 11 Dec 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 6,199 | $67.51 | $418.46K | 09 Dec 2025 | 11 Dec 2025 |
| SHERMAN MARK ANDREWEVP, Gen. Counsel & Secretary | Sale | 4,500 | $67.56 | $304.04K | 01 Dec 2025 | 03 Dec 2025 |
| Mark Andrew ShermanEVP, Gen. Counsel & Secretary | Sale | 4,500 | $67.56 | $304.04K | 01 Dec 2025 | 03 Dec 2025 |
| Prophet Tony A | Sale | 3,300 | $67.85 | $223.91K | 25 Nov 2025 | 26 Nov 2025 |
| Tony A ProphetDirector | Sale | 3,300 | $67.85 | $223.91K | 25 Nov 2025 | 26 Nov 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 36,699 | $66.91 | $2.46M | 24 Nov 2025 | 26 Nov 2025 |
| Kevin J YeamanPresident and CEO | Sale | 36,699 | $66.91 | $2.46M | 24 Nov 2025 | 26 Nov 2025 |
| Revankar ShriramSVP, Advanced Technology Group | Sale | 3,000 | $65.55 | $196.65K | 21 Nov 2025 | 24 Nov 2025 |
| Shriram RevankarSVP, Advanced Technology Group | Sale | 3,000 | $65.55 | $196.65K | 21 Nov 2025 | 24 Nov 2025 |
| Couling John DSVP, Entertainment | Sale | 6,164 | $66.12 | $407.56K | 20 Nov 2025 | 24 Nov 2025 |
| John D CoulingSVP, Entertainment | Sale | 6,164 | $66.12 | $407.56K | 20 Nov 2025 | 24 Nov 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 13,786 | $69.17 | $953.62K | 14 Oct 2025 | 16 Oct 2025 |
| YEAMAN KEVIN JPresident and CEO | Sale | 11,214 | $68.51 | $768.22K | 14 Oct 2025 | 16 Oct 2025 |
| Kevin J YeamanPresident and CEO | Sale | 11,214 | $68.51 | $768.22K | 14 Oct 2025 | 16 Oct 2025 |
| Kevin J YeamanPresident and CEO | Sale | 13,786 | $69.17 | $953.62K | 14 Oct 2025 | 16 Oct 2025 |
Frequently Asked Questions
What is DLB stock price today?
DOLBY LABORATORIES INC (DLB) is currently trading at $64.41. The stock has a 52-week range of $60.14 to $83.78 and a market capitalization of $6.15B.
Is DLB a good stock to buy in 2026?
DOLBY LABORATORIES INC has a P/E ratio of 26.1 (forward P/E: 13.9), a dividend yield of 2.11%, and 1-year performance of -20.0%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling DLB stock?
There have been 29 insider transactions for DLB in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has DLB stock performed over the past year?
DOLBY LABORATORIES INC (DLB) has returned -20.0% over the past 12 months. The stock traded between $60.14 and $83.78 during this period, and is currently at $64.41.
Which hedge funds own DLB (DOLBY LABORATORIES INC)?
0 tracked hedge funds currently hold DLB in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is DLB's market cap and valuation?
DOLBY LABORATORIES INC (DLB) has a market capitalization of $6.15B. The trailing P/E ratio is 26.1 and forward P/E is 13.9. The stock is classified in the Industrials sector.
What is DLB's revenue and profitability?
DOLBY LABORATORIES INC reported revenue of $1.34B with net income of $240.52M and a profit margin of 0.18%. The stock has a beta of 0.84.
What sector is DLB in and who are its biggest institutional holders?
DOLBY LABORATORIES INC (DLB) operates in the Industrials sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.